Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Wave Life Sciences reports transformative 2022 with promising clinical advancements

Wave Life Sciences showcased strong clinical progress and financial discipline in Q4 2022.
The collaboration with GSK and advancements in RNA editing and RNAi technologies position Wave for future success.
Despite challenges in increased expenses, Wave's focus on innovative therapies and strategic partnerships bode well for their future.

Wave Life Sciences reports Q1 progress, poised for RNA innovation

Wave Life Sciences showcased strong financial performance, significant program advancements, and a leadership position in RNA editing technology during Q1 2023.
The company's strategic shift, collaboration with GSK, and focus on additional endpoints beyond traditional measures highlight their commitment to innovation and patient outcomes.
While facing challenges in study designs and editing efficiency assessments, Wave's opportunities lie in differentiation, partnerships, and further advancements in precision medicine.

Wave Life Sciences advances RNA editing technology and secures key collaborations

Wave Life Sciences showcased strong progress in RNA editing and clinical programs, bolstered by collaborations and financial stability.
While facing challenges in off-target effects and patient selection, Wave aims to demonstrate leadership in protein restoration through RNA editing.
Anticipated milestones from GSK, advancements in AIMer technology, and upcoming trial data offer promising opportunities for Wave's growth.

Wave Life Sciences reports strong Q3 earnings and advances RNA pipeline

Wave Life Sciences demonstrated financial strength with positive net income and a healthy cash position.
The company's focus on RNA medicine pipeline advancement and collaborations with GSK show promise for future growth.
Challenges lie in addressing questions on program development, treatment functionality, and ensuring treatment efficacy and patient compliance.

Wave Life Sciences reports successful 2023, eyes growth in RNA editing and obesity programs

Wave Life Sciences had a successful year in 2023, with promising advancements in key programs and a stable financial position.
The company faces challenges in managing expenses and meeting high expectations for upcoming clinical data readouts.
However, Wave's strengths lie in its innovative RNA editing technology, diversified pipeline, and collaborations for revenue generation.
Opportunities abound in market differentiation, revenue growth, and addressing unmet medical needs through their unique programs.

Wave Life Sciences reports Q1 loss but shows promise in therapies

Wave Life Sciences is making strides in advancing their therapeutic portfolio with promising clinical trial progress and positive preclinical results.
While facing challenges in program validation and expansion, the company's strong R&D efforts and financial stability position them well for future growth.
With upcoming milestones and a focus on innovative therapies, Wave has opportunities to establish itself as a key player in the biopharmaceutical industry.

Wave Life Sciences reports breakthroughs in RNA editing and clinical progress

Wave Life Sciences showcased a successful quarter with advancements in RNA editing and positive clinical trial outcomes, positioning the company for future growth.
While facing financial challenges, the company's strong cash position and promising pipeline present opportunities for sustained innovation and market expansion.
Navigating regulatory pathways for accelerated approvals and leveraging breakthrough technologies underscore Wave's potential for long-term success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET.

Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference

Delcath Systems

Nkarta, Inc.

The Oncology Institute

As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.

Penny Stocks To Buy Now? 4 To Watch Before 2024

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd.'s stock WVE, -30.57% tumbled 31% Thursday, after the clinical-stage pharma company priced a $100 million secondary share offering at $5 a share, or a discount over its closing price Wednesday at $6.87.

Wave Life Sciences stock slides 31% after company prices $100 million secondary share offering

CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about December 11, 2023, subject to customary closing conditions.

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET.

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call.

Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript

Initiated RestorAATion clinical program for WVE-006, industry's first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism data anticipated in 2024

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, November 9, 2023, to review the company's third quarter 2023 financial results and provide business updates.

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave's best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023. Dr. Bolno will participate in the ADAR Editing Panel at 9:30 a.m. ET and an analyst-led fireside chat at 10:30 a.m. ET.

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

Beam Therapeutics

Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.

2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK and Takeda, with the GSK deal potentially worth up to $3.3 billion in milestone payments.

Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available to view beginning on Monday, September 11, 2023, at 7:00 a.m. ET.

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce levels of mutant Z-AAT protein, thereby addressing alpha-1 antitrypsin deficiency-related lung disease, liver disease or both

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call.

Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript

Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.62 per share a year ago.

Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates

Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate  (WVE-006), the industry's first RNA editing clinical candidate

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 3, 2023, to review the company's second quarter 2023 financial results and provide business updates.

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 2000® and broad-market all-cap Russell 3000® Indexes as part of the annual reconstitution, effective after the U.S. market opens today, June 26, 2023.

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

News for Wave Life Sciences Stock (WVE)